19 firms in India to make Pfizer’s oral COVID-19 antiviral drug

They have signed sublicence agreements with United Nations-backed Medicines Patent Pool

Updated - March 18, 2022 09:09 am IST

Published - March 18, 2022 01:40 am IST - HYDERABAD

The Pfizer logo is displayed at the company’s headquarters in New York

The Pfizer logo is displayed at the company’s headquarters in New York | Photo Credit: AP

Nineteen drugmakers in India have signed sublicence agreements with the United Nations-backed Medicines Patent Pool (MPP) to manufacture the generic version of Pfizer’s oral COVID-19 antiviral nirmatrelvir, which is to be used in combination with ritonavir.

They are among the 35 companies across 12 countries to have entered into such agreements with MPP for manufacturing and supplying to 95 low and middle income countries, including India. The non-exclusive sublicences allow the generic manufacturers to produce raw ingredients for nirmatrelvir and/or the finished drug itself co-packaged with ritonavir.

The agreements follow the voluntary licensing agreement MPP and Pfizer signed in November 2021. Pfizer markets its oral COVID-19 treatment under the name of Paxlovid, which has received emergency use/conditional authorisation from USFDA and the UK Medicines and Healthcare products Regulatory Agency (MHRA).

Of the 35, six companies will focus on producing the drug substance, nine will produce the drug product and the rest will do both. Pfizer will not receive royalties from sales of nirmatrelvir from the MPP sublicensees so long as COVID-19 remains classified as a Public Health Emergency of International Concern by the WHO.

International standards

MPP said the companies offered the sublicence demonstrated their ability to meet its requirements related to production capacity, regulatory compliance, as well as international standards for quality-assured medicines.

“Nirmatrelvir is a new product and requires substantial manufacturing capabilities to produce. We have been very impressed with the quality of manufacturing demonstrated by these companies,” MPP Executive Director Charles Gore said.

Sun Pharma, Biocon, Aurobindo Pharma, Cadila, Torrent Pharma, Strides, MSN Pharma, Laurus Labs, Granules, Divis Laboratories, Glenmark, Cipla, Emcure, Viatris, Amneal, Arene Lifesciences, Macleods, SMS Pharmaceuticals and Hetero are the 19 drugmakers to receive the sublicence.

Besides from India, the other companies are in Bangladesh, Brazil, China, Dominican Republic, Jordan, Israel, Mexico, Pakistan, Serbia, South Korea and Vietnam. MPP said a licence had also been offered to a company in Ukraine and the offer would remain available as the firm was not able to sign due to the current conflict.

Aurobindo Vice-Chairman and Managing Director K. Nithyananda Reddy said the company had already developed and commercialised ritonavir which is used as a booster along with nirmatrelvir. “We are excited to work on this molecule and will soon make it available commercially at an affordable price for these markets after due process of registration and approval in various countries, including the DCGI in India,” he said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.